0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Antioxidants for Alzheimer Disease—Reply

Douglas R. Galasko, MD; Paul Aisen, MD
JAMA Neurol. 2013;70(2):270-271. doi:10.1001/jamaneurol.2013.935.
Text Size: A A A
Published online

Extract

In reply

We thank Dr Praticò for his correspondence. The doses of vitamins and coenzyme Q (CoQ) that we used are consistent with studies where plasma levels were monitored.1,2 We evaluated compliance by pill counts at visits at weeks 8 and 16, which indicated more than 90% compliance for subjects analyzed in each treatment arm.3 Subjects and caregivers denied taking additional (nonpermitted) antioxidants during the study. In view of the absence of effects on cerebrospinal fluid (CSF) biomarkers in our study, we did not pursue plasma or CSF measures of CoQ. Although plasma levels of CoQ show proportional increases in relation to dosing,2 the value of plasma or CSF levels to predict brain levels of this highly lipophilic coenzyme are not clear. Equivalent doses of CoQ from different suppliers may result in widely different blood levels,2 and we were not able to explore this important aspect of CoQ bioavailability before designing our study. Attempts to improve the bioavailability of CoQ are underway,4 and further studies of novel preparations with better brain penetration may be worth pursuing in the future. The question of whether dietary or low doses of supplemental vitamins and CoQ that were permitted could have masked changes in oxidative stress responses due to the treatment interventions is potentially interesting, although difficult to test definitively. Comparison groups of patients with Alzheimer disease and healthy control subjects who were not taking any antioxidant supplements at all would be necessary to address this question. The F2-isoprostane assays were run in a single batch; a reference range for F2-isoprostanes in CSF from healthy subjects run by Montine Laboratory during the same period was 15 pg/mL to 40 pg/mL (90% CI).

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

February 1, 2013
Domenico Praticò, MD
JAMA Neurol. 2013;70(2):270-271. doi:10.1001/jamaneurol.2013.613.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();